Journal of Vaccine Research 2024, Vol.14, No.5, 217-230 http://medscipublisher.com/index.php/jvr 230 Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., Bibi S., Briner C., Cicconi P., Collins A.M., Colin-Jones R., Cutland C.L., Darton T.C., Dheda K., Duncan C.J.A., Emary K.R.W., Ewer K.J., Fairlie L., Faust S.N., Feng S., Ferreira D.M., Finn A., Goodman A.L., Green C.M., Heath P.T., Hill C., Hill H., Hirsch I., Hodgson S.H.C., Izu A., Jackson S., Jenkin D., Joe C.C.D., Kerridge S., Koen A., Kwatra G., Lazarus R., Lawrie A.M., Lelliott A., Libri V., Lillie P.J., Mallory R., Mendes A.V.A., Milan E.P., Minassian A.M., McGregor A., Morrison H., Mujadidi Y.F., Nana A., O’Reilly P.J., Padayachee S.D., Pittella A., Plested E.M., Pollock K.M., Ramasamy M.N., Rhead S., Schwarzbold A.V., Singh N., Smith A., Song R., Snape M.D., Sprinz E., Sutherland R.K., Tarrant R., Thomson E.C., Török M.E., Toshner M., Turner D.P.J., Vekemans J., Villafana T.L., Watson M.E.E., Williams C.J., Douglas A.D., Hill A.V.S., Lambe T., Gilbert S.C., Pollard A.J., and Oxford COVID Vaccine Trial Group, 2020, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet (London, England), 397(10269): 99-111. https://doi.org/10.1016/S0140-6736(20)32661-1 PMID: 33306989 PMCID: PMC7723445 Xu L.H., Feng T.T., and Fang K.Y., 2024, Safety and efficacy of mRNA vaccines: insights from clinical trials, International Journal of Clinical Case Reports, 14(3): 117-131. https://dx.doi.org/10.5376/ijccr.2024.14.0014 Xu W., and Li J.H., 2024, Peptide-based vaccines for oral cancer: mechanisms of action and clinical outcomes, International Journal of Clinical Case Reports, 14(3): 132-143. https://dx.doi.org/10.5376/ijccr.2024.14.0015 Xu S.Q., Yang K.P., Li R.S., and Zhang L., 2020, mRNA vaccine era—mechanisms, drug platform and clinical prospection, International Journal of Molecular Sciences, 21(18): 6582. https://doi.org/10.3390/ijms21186582 PMID: 32916818 PMCID: PMC7554980 Zhou F., Hansen L., Pedersen G., Grødeland G., and Cox R., 2021, Matrix M adjuvanted H5N1 vaccine elicits broadly neutralizing antibodies and neuraminidase inhibiting antibodies in humans that correlate with in vivo protection, Frontiers in Immunology, 12: 747774. https://doi.org/10.3389/fimmu.2021.747774 PMID: 34887855 PMCID: PMC8650010 Zhu F.C., Guan X.H., Li Y.H., Huang J.Y., Jiang T., Hou L.H., Li J.X., Yang B.F., Wang L., Wang W.J., Wu S.P., Wang Z., Wu X.H., Xu J.J., Zhang Z., Jia S.Y., Wang B.S., Hu Y., Liu J.J., Zhang J., Qian X.A., Li Q., Pan H.X., Jiang H.D., Deng P., Gou J.B., Wang X.W., Wang X.H., and Chen W., 2020, Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet, 396(10249): 479-488. https://doi.org/10.1016/S0140-6736(20)31605-6 PMID: 32702299 PMCID: PMC7836858
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==